Search results
Added:
2 months ago
Source:
Cardiac Failure Review
Single-pill low-dose combination (LDC) therapy is an emerging strategy for improving blood pressure (BP) control in patients with hypertension.¹ Two new phase III trials, HM-APOLLO-301 and HM-APOLLO-302, have evaluated the efficacy and safety of an ultra-low-dose triple combination pill compared with standard-dose monotherapy as an initial treatment for mild-to-moderate hypertension…
View more
Added:
1 year ago
ACC 25 - The API-CAT Study shows reduced-dose apixaban is non-inferior to full-dose apixaban for extended anticoagulation in patients with active cancer who have completed 6 months of anticoagulant therapy for venous thromboembolism (VTE).Late-Breaker host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Prof Isabelle Mahe (Paris Cite University, Paris, FR) to discuss the…
View more
Lukas Lehmkuhl
Research Area(s) / Expertise:
Job title: Head of the Computed Tomography (CT) Unit
Author
Added:
1 year ago
This week on Parallax, Dr Ankur Kalra welcomes Eric Radtke, Vice President at Worldwide Innovations & Technologies, Inc, and Barbara Breininger, a cardiovascular radiologic technologist and clinical manager with 26 years of experience.This special episode dives deep into the crucial topic of radiation hygiene, exploring it from the perspectives of both manufacturers and users of radiation safety…
View more
Added:
1 month ago
William G Breen
Author
Zalunfiban before PCI
Added:
2 months ago
Editorial
Added:
1 year ago
ACC 2025 - 540-day follow up of lepodisiran in patients with elevated lipoprotein(a) (Lp(A)) shows the extended duration of action of lepodisiran will allow infrequent dosing in the ongoing cardiovascular outcome trial.Dr Steven Nissen (Cleveland Clinic, Cleveland, US) joins us onsite at ACC to discuss the ALPACA phase 2 trial (NCT05565742), investigating the safety and efficacy of lepodisiran,…
View more
Raymond Mak
Author